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Abstract 
Methylphenidate mainly enhances dopamine neurotransmission whereas 3,4-
methylenedioxymethamphetamine (MDMA, “ecstasy”) mainly enhances serotonin 
neurotransmission. However, both drugs also induce a weaker increase of cerebral 
noradrenaline exerting sympathomimetic properties. Dopaminergic psychostimulants are 
reported to increase sexual drive, while serotonergic drugs typically impair sexual arousal 
and functions. Additionally, serotonin has also been shown to modulate cognitive perception 
of romantic relationships. Whether methylphenidate or MDMA alter sexual arousal or 
cognitive appraisal of intimate relationships is not known. Thus, we evaluated effects of 
methylphenidate (40mg) and MDMA (75mg) on subjective sexual arousal by viewing erotic 
pictures and on perception of romantic relationships of unknown couples in a double-blind, 
randomized, placebo-controlled, crossover study in 30 healthy adults. Methylphenidate, but 
not MDMA, increased ratings of sexual arousal for explicit sexual stimuli. The participants 
also sought to increase the presentation time of implicit sexual stimuli by button press after 
methylphenidate treatment compared with placebo. Plasma levels of testosterone, estrogen, 
and progesterone were not associated with sexual arousal ratings. Neither MDMA nor 
methylphenidate altered appraisal of romantic relationships of others. The findings indicate 
that pharmacological stimulation of dopaminergic but not of serotonergic neurotransmission 
enhances sexual drive. Whether sexual perception is altered in subjects misusing 
methylphenidate e.g., for cognitive enhancement or as treatment for attention deficit 
hyperactivity disorder is of high interest and warrants further investigation. 
 
Keywords: MDMA, methylphenidate, sexual arousal, couples appraisal  
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Introduction  
Methylphenidate is a stimulant drug used for the treatment of attention deficit 
hyperactivity disorder, but it is also misused as a club drug and a cognitive enhancer (Maier 
et al., 2013). 3,4-Methylenedioxymethamphetamine (MDMA; “ecstasy”) is a popular 
recreational drug used primarily because of its empathogenic properties, i.e. the drug 
increases feelings of sociability and closeness to others (Hysek et al., 2013; Morgan et al., 
2013). Additionally, both drugs also have psychostimulant properties (Hysek et al., 2014). 
It is well recognized that psychoactive substances affect sexual behavior. Users of 
psychostimulants including cocaine and methamphetamine report increased sexual desire 
and arousal and enhanced sexual pleasure (Frohmader et al., 2010; Rawson et al., 2002; 
Semple et al., 2002). In contrast, ecstasy users described inconsistent effects of MDMA on 
sexual desire (McElrath, 2005; Passie et al., 2005; Theall et al., 2006). Specifically, most 
users report no desire for penetrative sex but only increased feelings of sensuality, whereas 
some (in particular gay and bisexual females) use MDMA in particular for sexual 
enhancement (McElrath, 2005). In another survey, similar proportions of users reported 
increased or decreased interest in initiating sexual activity while on MDMA (Buffum and 
Moser, 1986). Additionally, sexual performance seems to be consistently impaired by the 
drug (Buffum and Moser, 1986; Passie et al., 2005; Zemishlany et al., 2001). Thus, MDMA 
induces well-being and feelings of closeness to others (Hysek et al., 2013) accompanied by 
a sensual rather than a sexual enhancement (Passie et al., 2005).   
However, research on psychoactive drug use and sexual behavior is typically based on 
interviews of drug users and has mainly focused on sexual risk taking (McElrath, 2005; 
Rawson et al., 2002; Semple et al., 2002; Theall et al., 2006). Few studies have objectively 
evaluated sexual arousal in stimulant drug users (Aguilar de Arcos et al., 2008) or 
investigated the effects of acute administration of a psychostimulant on sexual perception 
(Volkow et al., 2007). In particular, intravenous administration of methylphenidate at a high 
dose of 0.5 mg/kg body weight has been shown to enhance self-reported sexual desire 
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(Volkow et al., 2007) while administration of a moderate oral dose of methylphenidate (20 
mg) had no effects (Volkow et al., 2007). Finally, to our knowledge there are no experimental 
data on the effects of MDMA on sexual perception and arousal.  
Methylphenidate increases dopamine (DA) and norepinephrine (NE) neurotransmission 
by DA and NA reuptake inhibition (Schmeichel and Berridge, 2013), while MDMA mainly 
releases serotonin (5-hydroxytryptamine, 5-HT) but also NE (Hysek et al., 2012b). While DA 
is thought to facilitate sexual drive, 5-HT is stated to inhibit sexual arousal and function 
(Fabre-Nys, 1998; Frohmader et al., 2010; Melis and Argiolas, 1995; Passie et al., 2005; 
Pfaus, 2009; Zemishlany et al., 2001). For example, dopaminergic antiparkinson therapy is 
associated with hypersexuality (Kelley et al., 2012; Uitti et al., 1989; Weintraub et al., 2010) 
whereas decreased libido and sexual dysfunction are common adverse effects of 
serotonergic antidepressants (Serretti and Chiesa, 2009). Accordingly, we hypothesized that 
methylphenidate (40 mg), predominantly enhancing DA, would increase sexual arousal in a 
Sexual Arousal Task (SAT), while MDMA (75 mg), mainly increasing 5-HT, would not. 
Because sex hormones may alter sexual arousal (Meston and Frohlich, 2000), we measured 
testosterone, estrogen, and progesterone plasma levels and explored possible associations 
with sexual arousal ratings.  
Besides from having effects on sexual desire and emotion, psychoactive drugs may 
also influence aspects of the cognitive appraisal of romantic partnerships. For example, 
MDMA has been shown to acutely alter related components of social cognition including 
recognition of facial emotions (Bedi et al., 2010; Hysek et al., 2012a; Hysek et al., 2013; 
Hysek et al., 2014; Kirkpatrick et al., 2014) and emotional empathy (Hysek et al., 2013; 
Kuypers et al., 2014; Schmid et al., 2014). Additionally, changes in 5-HT levels may influence 
cognitions sustaining intimate relationships. Specifically, healthy volunteers perceived 
photographed couples as being less intimate and romantic after lowering cerebral 5-HT 
levels by tryptophan depletion (Bilderbeck et al., 2011). In contrast, sub-chronic 
administration of the selective 5-HT reuptake inhibitor (SSRI) citalopram increased perceived 
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worth of mutual trust in relationships and reduced importance attributed to physical and 
intimate aspects of the participants’ own relationship (Bilderbeck et al., 2014). We therefore 
evaluated the effect of a 5-HT releaser (MDMA) and a DA and NA reuptake inhibitor 
(methylphenidate) on cognitive appraisal of intimate relationships. We hypothesized that 
MDMA, but not methylphenidate, would increase ratings of intimacy and romance in the 
Couples Appraisal Task (CAT) (Bilderbeck et al., 2011; Bilderbeck et al., 2014) parallel to its 
5-HT enhancing, empathogenic and prosocial effects (Hysek et al., 2013; Kirkpatrick et al., 
2014).  
 
Experimental Procedures 
Experimental protocol 
We used a double-blind, placebo-controlled, cross-over design in 30 subjects each treated 
with methylphenidate (40mg), MDMA (75 mg), and placebo, resulting in 90 assessments. 
The order of the three experimental sessions was balanced (Latin Square design), and the 
washout periods between sessions were at least seven days. The study was conducted in 
accordance with the Declaration of Helsinki and approved by the local Ethics Committee and 
the Swiss Agency for Therapeutic Products (Swissmedic). The study was registered at 
ClinicalTrials.gov (NCT01616407). All of the subjects provided written informed consent 
before participating in the study and were paid for their participation. 
 
Participants 
Thirty healthy subjects (15 men, 15 women) with a mean age of 24 ± 4.2 years (mean ± SD; 
range 18 to 32 years) were recruited from the University of Basel. All subjects were self-
reported heterosexuals. Inclusion criteria were age 18 to 45 years and body mass index 18 
to 27 kg/m2. The exclusion criteria were a history of psychiatric disorders (determined by the 
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Structured Clinical Interview for Axis I and II Disorders according to the Diagnostic and 
Statistical Manual of Mental Disorders, 4th edition) or chronic or acute physical illness 
(assessed by physical examination, electrocardiogram, standard hematology, and chemical 
blood analysis). Additional exclusion criteria were pregnancy, tobacco smoking (>10 
cigarettes/day), a lifetime history of using illicit drugs more than five times, with the exception 
of past cannabis use, and any illicit drug use including cannabis within the last two months or 
during the study period, determined by urine tests conducted during screening and before 
the test sessions using TRIAGE 8 (Biosite, San Diego, California). Twenty-two subjects were 
“ecstasy”/MDMA-naive. Eight subjects had used MDMA less than five times. One subject 
reported previous single use of methylphenidate as cognitive enhancer. Six female 
participants used hormonal contraception. The female subjects who did not use hormonal 
contraception were investigated during the follicular phase (day 2 to 14). 
Study drugs 
±MDMA hydrochloride (Lipomed AG, Arlesheim, Switzerland) was prepared as gelatin 
capsules with mannitol as filler. Identical placebo (only mannitol) capsules were prepared. 
MDMA was administered in a single absolute dose of 75 mg corresponding to 1.1 ± 0.13 
mg/kg body weight (range 0.8-1.3 mg/kg body weight). This dose of MDMA corresponds to 
that typically found in a single ecstasy pill (Brunt et al., 2012). Immediate-release 
methylphenidate tablets (4×10 mg, Ritalin, Novartis AG, Bern, Switzerland) were 
encapsulated within opaque gelatin capsules (with mannitol as filler), and identical placebo 
capsules (mannitol pill plus mannitol filler) were prepared. This is a typical and well-tolerated 
clinical and research dose of methylphenidate (Korostenskaja et al., 2008) producing similar 
cardiovascular stimulation to the dose of MDMA used (Schmid et al., 2014). 
 
Study procedures 
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The experimental sessions took place in a quiet hospital research ward with no more than 
two research subjects of the same sex present per session. Before the first session, subjects 
completed a brief training to get familiarized with the computer tasks. Drug administration 
was at 10:00 AM. The SAT and CAT were performed at 150 and 170 minutes after drug 
administration, respectively, when maximal plasma levels of the drugs were expected (Hysek 
et al., 2014). The actual times to peak concentration were (mean±SD) 153±50 and 130±48 
min after MDMA and methylphenidate administration, respectively, as reported together with 
the concentration-time curves (Schmid et al., 2014). A standardised small lunch was served 
at 13:30 PM. Subjects were sent home at 4:30 PM. During the day, subjective effects, vital 
signs and adverse drug effects were assessed as reported elsewhere (Schmid et al., 2014). 
Additional test of emotion recognition and empathy were performed 75-105 min after drug 
administration as reported elsewhere (Schmid et al., 2014).  
Measures 
Sexual Arousal Task 
The SAT included 16 colour photographs taken from the International Affective Picture 
System (IAPS) (Lang et al., 2008), as similarly used by others (Aguilar de Arcos et al., 2008). 
There were eight neutral and eight erotic or sexual pictures. Neutral pictures showed 
landscapes, objects, or persons without sexual signals. Erotic pictures included four implicit 
sexual scenes (i.e., no primary or secondary sexual organs are shown explicitly but persons 
were shown in stimulating poses showing some skin) and four explicit sexual scenes (i.e., 
clearly pornographic poses or scenes). In the neutral (persons), implicit and explicit 
condition, two pictures with single persons and two pictures with couples were shown, 
respectively. Thus, we had four pictures of neutral objects (two) and landscapes (two), four 
pictures of neutral persons (two singles and two couples), four pictures of implicit sexual 
scenes (two singles and two couples), and four pictures of explicit erotic scenes (two singles 
and two couples). Additionally, there was a male and a female version of the test: female 
subjects were only shown males in the single person condition, while male subjects received 
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only female single person stimuli. Because men and women were tested on different tasks, 
scores cannot be compared directly. The SAT included two subtasks, an “effort task” and an 
“arousal rating task”. In the effort task, pictures were shown for one sec. To prolong the 
presentation, participants were instructed to click rapidly on the keyboard for as long as they 
wanted to see the picture. One or more clicks per sec resulted in a prolongation of the 
presentation by another sec until no more clicks occurred within one sec. Outcome measures 
were the total number of clicks and the resulting duration the picture was presented. In the 
arousal rating task, participants were asked to rate each picture on 5 dimensions. The 
dimensions included “pleasant”, “arousing/exciting”, “attractive”, “likeable”, and “erotic”. The 
original Self-Assessment Manikin were used for the affective dimensions valence (“pleasant”) 
and arousal (“”arousing/exciting”) (Bradley and Lang, 1994), resulting in a 9-point rating 
scale. Ratings for “attractive”, “likeable” and “erotic” were performed on a 9-point rating scale 
marked “not at all” on the left and “very” on the right end. Ratings of all neutral, implicit sexual 
or explicit sexual pictures were averaged for each dimension. The SAT was implemented in 
Presentation Version 14.8 (Neurobehavioral Systems, Albany, CA, USA) and shown on a 
computer screen. 
Couples Appraisal Task  
To assess the appraisal of intimate relationships we used a German adaptation of the 
previously described CAT (Bilderbeck et al., 2011; Bilderbeck et al., 2014). Briefly, 18 
photographs of heterosexual couples in genuine relationships were presented on a computer 
screen. All facial expressions were broadly neutral. Nine couples showed physical contact 
such as affiliative or romantic gestures and nine couples were standing apart and were not 
touching each other. Touching and non-touching couples were randomly mixed. Participants 
rated each couple using visual analogue scales (0-10) with “not at all” and “very” as anchor 
points for the following descriptors, which were selected to display subjects’ perceived 
ratings of relationship stability (Bilderbeck et al., 2011; Bilderbeck et al., 2014): “intimate”, 
“romantic”, “supportive”, “trusting”, “conflict resolution”, “enduring”, and “good physical 
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relationship”. Ratings of “turbulence” and “bickering” were used as negative relationship 
characteristics. Additionally, “dominance” and “balance of love” were rated using scales 
labelled with “man” on the left and “woman” on the right, with “neutral” at the midpoint. 
Participants’ ratings for each of the descriptors were then averaged over touching and non-
touching couples. The CAT was also implemented in Presentation Version 14.8 
(Neurobehavioral Systems, Albany, CA, USA).  
Endocrine measures 
Plasma levels of testosterone (men and women), estradiol and progesterone (only women) 
were measured at baseline and 2 h after drug administration using commercial electro-
chemiluminescence immunoassays (Cobas ®, Roche Diagnostics, Basel, Switzerland).  
Data analysis 
Statistical analysis was performed using Statistica 12 (StatSoft, Tulsa, OK, USA). SAT data 
were analysed using analyses of variance (ANOVAs) with drug (methylphenidate, MDMA, 
placebo) and sexual content (neutral, implicit, explicit) as within-subject factors. Drug effects 
on ratings of couples in the CAT were similarly analysed using ANOVAs with drug and 
touching (touching vs. non-touching) as within-subject factor. ANOVAs were also used to 
compare hormone levels (differences from baseline, ΔEmax). Tukey post hoc were performed 
based on significant main effects or interactions. Sex-differences were assessed with sex 
added to the ANOVAs as between-subject factor for each descriptor.  Additional ANOVAs 
were performed with drug order to exclude carry-over effects. Spearman’s rank correlations 
were used to determine associations between measures. Differences associated with p-
values lower than 0.05 (two-tailed) were considered statistically significant. 
 
Results 
Sexual Arousal Task 
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Data from two women and two men were missing for the SAT effort task and for two women 
for the SAT arousal task due to technical problems. Effects of methylphenidate and MDMA 
on SAT scores are shown in Table 1 and Figure 1.  
In the effort subtask, there were significant drug × sexual content interactions for both the 
number of clicks and the duration of the presentation [F(4,100)=2.6; p<0.05 and 
F(4,100)=3.0, p<0.05; respectively]. There was a significant main effect of sexual content 
(neutral, implicit, explicit) on both the number of clicks [F(2,50)=18.3; p<0.001] and on the 
duration of the presentation [F(2,50)=22.2; p<0.001]. The total number of clicks was lower for 
explicit compared with implicit and neutral stimuli (both p<0.001). Both, methylphenidate and 
MDMA increased the number of clicks for implicit sexual stimuli compared with placebo 
(p<0.001 and p<0.01, respectively). Only methylphenidate also significantly increased the 
presentation time for the sexual implicit stimuli compared with placebo (p<0.05). 
In the arousal subtask, there were significant main effects of sexual content (neutral, implicit, 
explicit) for all ratings [all F(2,54)>50; p<0.001]. Implicit sexual content increased ratings on 
all dimensions compared with neutral contents (all p<0.001, Table 1) and ratings were also 
mostly higher compared with explicit sexual contents (most p<0.001). Explicit sexual content 
also increased ratings of arousal/excitement, attractiveness, and erotic. There was a 
significant drug × sexual content interaction on ratings of “arousing/exciting” [F(4,108) = 3.59; 
p<0.01]. Methylphenidate significantly increased ratings of arousal/excitement compared with 
placebo (p<0.01) or MDMA (p<0.001) for pictures with an explicit sexual content. 
Methylphenidate similarly tended to increase ratings of erotic compared with placebo and 
MDMA [F(4,108) = 2.17; p=0.08; both post hoc tests: p<0.05] (Table 1). MDMA did not alter 
any ratings compared with placebo. The findings remained largely the same when an 
analysis was altered to include, for the neutral condition, only the pictures displaying persons 
(i.e. excluding landscape and object pictures). Finally, introducing the additional factor 
“number of shown persons” (singles vs. couples) did also not change the results and the 
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factor itself was also not significant. Surprisingly, there were no significant differences 
between male or female participants in any of the ratings or drug effects.  
Couples Appraisal Task  
Drug effects in the CAT are shown in Figure 2. There were no drug effects on any of the 
descriptors in the CAT, indicating that neither methylphenidate nor MDMA altered appraisal 
of intimate relationship. In line with previous studies (Bilderbeck et al., 2011; Bilderbeck et 
al., 2014), ratings of all relationship stability descriptors (“intimate”, “romantic”, “supportive”, 
“trusting”, “conflict resolution”, “enduring”, and “good physical relationship”) were significantly 
increased for touching couples compared with couples who were standing apart [F(1.28)>10; 
p<0.01 for all descriptors]. Again, no sex differences or sex × drug interactions were 
observed.  
Endocrine measures 
Drug effects on plasma levels of testosterone, estradiol, and progesterone are shown in 
Table 2. There were no significant correlations between plasma sex hormone levels and 
sexual arousal ratings after any of the drugs (drug-induced changes or change scores 
[Δplacebo-drug]). There was a significant main effect of drug on testosterone in women 
[F(2,28)=5.392; p<0.02] with slightly higher levels after methylphenidate compared with 
placebo (p<0.05). Additionally, there was a significant main effect of drug on estradiol 
[F(2,28)=4.672; p<0.02], with higher levels after methylphenidate compared with MDMA 
(p<0.05).  
 
Discussion 
The present experimental study showed that healthy adults rated pictures with an 
explicit sexual content as more exciting after acute administration of methylphenidate 
compared with placebo or MDMA. Concurrently, methylphenidate increased the number of 
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responses (button presses) performed by the participants in order to prolong the presentation 
of images with an implicit sexual content and the actual presentation duration of these 
pictures. In contrast, MDMA had no effect on subjective arousal ratings of erotic pictures with 
implicit or explicit sexual content. However, similar to methylphenidate, MDMA also 
increased the number of responses for implicit sexual stimuli but the invested effort was too 
small to significantly prolong the presentation time. Surprisingly, none of the drugs altered 
appraisal of romantic relationships in a task previously shown to be sensitive to alterations in 
the 5-HT system (Bilderbeck et al., 2011; Bilderbeck et al., 2014).  
Psychostimulants are believed to acutely increase sexual arousal and drive, but such 
effects have rarely been evaluated using actual tests and in controlled settings. Consistent 
with our findings, methylphenidate has previously been shown to increase self-reports of 
sexual desire (Volkow et al., 2007). However, the effect of methylphenidate on sexual desire 
was observed only after intravenous administration of methylphenidate but not after oral 
administration of a moderate dose of 20 mg (Volkow et al., 2007). Additionally, subjects rated 
their sexual desire in the absence of any sexual stimuli and while lying in a tomograph 
(Volkow et al., 2007). In contrast, in our study, subjects were viewing pictures with implicit 
and explicit sexual content and we evaluated drug effects on subjective sexual arousal 
elicited by these visual sexual stimuli. Moreover, we administered a higher dose of 
methylphenidate (40 mg), which might lead to similar plasma levels as intravenous 
administration of a lower dose (20 mg) in the study of Volkow and colleagues (Volkow et al., 
2007). Consistent with the present findings, other stimulants with similar dopaminergic action 
including cocaine and methamphetamine have been subjectively reported to increase sex 
drive as well (Rawson et al., 2002) and are commonly linked with risk-associated sexual 
behaviours (Frohmader et al., 2010; Rawson et al., 2002). Furthermore, abstinent cocaine 
users also rated explicit erotic pictures from the IAPS as more pleasant compared with users 
of alcohol or heroin (Aguilar de Arcos et al., 2008).  
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The mechanisms underlying increased sexual arousal following administration of 
psychoactive substances have only partly been elucidated. It has been proposed that DA is 
responsible for the increase in sexual arousal following administration of methylphenidate or 
methamphetamine by disrupting conditioned inhibition of sexual arousal and behaviour 
(Volkow et al., 2007) although these drugs also enhance NE in addition to DA.  
MDMA did not enhance subjective sexual arousal ratings in response to visual stimuli 
in the present study. However, MDMA, similar to methylphenidate, significantly increased the 
number of clicks to potentially prolong the presentation of the implicit but not of the explicit 
sexual stimuli compared with placebo. Viewing implicit erotic pictures was rated as more 
pleasant compared with viewing explicit pornographic pictures in all drug conditions. Thus, 
MDMA increased responding only for erotic stimuli that were more pleasant to view. 
Interviews of recreational MDMA users documented that most respondents reported feelings 
of emotional closeness while consuming MDMA but without the desire for penetrative sex 
(McElrath, 2005). However, other respondents reported that MDMA increased their sexual 
arousal and some (in particular gay and bisexual females) had used MDMA specifically for 
sexual enhancement (McElrath, 2005). Another interview study found that ecstasy use 
seemed to increase sexual desire but not the ability to achieve an erection or orgasm (Theall 
et al., 2006; Zemishlany et al., 2001). Thus, MDMA mainly seems to enhance pleasure in 
touching and physical closeness rather than actual sexual engagement and is also reported 
to impair sexual performance (Frohmader et al., 2010; Passie et al., 2005; Theall et al., 2006; 
Zemishlany et al., 2001). Neurochemically, MDMA enhances 5-HT and NE and weakly also 
DA transmission (Hysek et al., 2012b) but additionally, MDMA also releases oxytocin and 
prolactin (Hysek et al., 2012a; Hysek et al., 2013). Dopamine, NE and oxytocin enhance and 
5-HT and prolactin inhibit sexual excitation (Kruger et al., 2005; Pfaus, 2009). Sexual 
dysfunction associated with serotonergic drugs has been shown to involve 5-HT1B, 5-HT2 and 
5-HT3 receptors (Fabre-Nys, 1998; Meston and Frohlich, 2000). In addition to releasing 5-HT 
and NE (Hysek et al., 2012b), MDMA also directly binds to serotonergic 5-HT2A-, 5-HT2B-, 
and 5-HT2C-receptors (Simmler et al., 2013; Teitler et al., 1990). It is likely that the 
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serotonergic effects predominate in this neurochemical cocktail, resulting in the absence of 
sexually enhancing or even presence of impairing effects for MDMA at the doses typically 
used by humans.  
Sexual stimuli and behaviour activate the mesolimbic DA reward system similarly to 
other rewarding/pleasant stimuli or drugs of abuse (Georgiadis and Kringelbach, 2012; 
Holstege et al., 2003). Our study findings are consistent with the role for DA in sexual arousal 
because methylphenidate increased sexual arousal and MDMA did not. In the case of 
MDMA, the additional release of NE may have had some small sexually enhancing effects, 
which were masked by concomitant 5-HT release, which is known to dampen sexual function 
(Pfaus, 2009). Consistent with our finding of increased sexual arousal after methylphenidate, 
the DA precursor levodopa enhanced the activation of the nucleus accumbens when 
subliminal sexual stimuli were shown, whereas the DA D2-receptor antagonist haloperidol 
decreased activations (Oei et al., 2012). Accordingly, the DA and NE transporter inhibitor and 
antidepressant bupropion, which has less side effects on sexual arousal and libido than 
serotonergic antidepressants, increased activation of brain regions related to sexual 
functioning (Abler et al., 2011). Moreover, flibanserin, which enhances NE and DA while 
reducing 5-HT (Borsini et al., 2002), increased sexual desire in women with hypoactive 
sexual desire (Katz et al., 2013). Finally, dextroamphetamine and methylphenidate have 
been reported to reverse the sexually impairing effects of 5-HT transporter blockers and to 
even enhance sexual arousal and function in female and male patients with depression 
(Bartlik et al., 1995).  
Although MDMA did not enhance sexual arousal in the present study, it appears to 
induce effects that may affect sexual interaction. In particular, MDMA increased feelings of 
closeness to others and sociability and alters sensual perception including touch (Hysek et 
al., 2013; Liechti et al., 2001; Schmid et al., 2014). Despite these emotional changes, MDMA 
did not alter the appraisal of romantic partnerships of others in the present study contrary to 
our expectation. It has previously been shown that presumably enhancing 5-HT tone with 
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citalopram across eight days increased ratings of trusting in the CAT and reduced the 
importance of physical and intimate aspects of the participant’s own relationships (Bilderbeck 
et al., 2014). Contrarily, lowering cerebral 5-HT by tryptophan depletion has changed ratings 
of relationship characteristics of photographed couples, including decreased intimacy and 
romance (Bilderbeck et al., 2014). Alterations in 5-HT levels did not only influence 
relationship characteristic ratings but also ratings of dominance with women providing higher 
ratings of male dominance after 5-HT reduction (Bilderbeck et al., 2011), and decreased 
ratings of turbulence and bickering in men after citalopram (Bilderbeck et al., 2014). 
However, MDMA was administered acutely while citalopram was administered chronically 
probably resulting in adaptive changes to the 5-HT system (Stahl, 1998). Additionally, MDMA 
is also less selective for the 5-HT system than citalopram (see above). Moreover, although 
MDMA stimulates 5-HT release much more than citalopram, it did not alter ratings of general 
relationship stability or indices of dominance and discord in the CAT. Thus, we might have 
“overstimulated” our participants as – similar to DA and NE neurotransmission – an inverted 
U-shaped function has also been postulated for the 5-HT system (Roiser et al., 2006). 
Interestingly, MDMA produced subjective feelings of trust and openness towards others 
(Schmid et al., 2014), thus producing effects that were very similar to those perceived 
important in others after citalopram administration (Bilderbeck et al., 2014).  
While pathologically low levels of testosterone result in decreased sexual interest and 
activity, variability in the normal/upper range is generally not considered to influence sexual 
interest or behavior in men (Meston and Frohlich, 2000). Similarly, estrogen and 
progesterone play only a minimal role in female sexual desire (Meston and Frohlich, 2000). 
We found that plasma levels of testosterone, estrogen, or progesterone were not associated 
with sexual arousal ratings in the present study. Consistently, different estrogen and 
progesterone levels exerted only minor effects on neural responses to explicit visual erotic 
stimulation in women (Abler et al., 2013).   
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The present study has several limitations. First, we used only single doses of MDMA 
and methylphenidate. However, the used doses of both drugs that produced similar 
cardiovascular stimulation (Schmid et al., 2014), indicating equipotent stimulant effects. 
Nevertheless, dose-response relationships are lacking as in most of such human 
neuropsychopharmacological experiments. As an important strength, we included two active 
drugs into the design allowing for comparisons of each active drug with both the placebo and 
another active drug condition. Second, only acute drug effects were assessed and the impact 
of chronic use of methylphenidate or MDMA on the present measures remains unknown. 
Third, sexual stimuli were presented without time limit. It has previously been shown that 
exposure to supraliminal sexual images showed activation in both arousal- but also control-
related brain areas (Gillath and Canterberry, 2012). Men presumably show higher sexual 
drive (Baumeister et al., 2001), but may also exhibit stronger urge to control it when being 
consciously aroused, therefore resulting in similar arousal ratings than women. Future 
studies will have to examine drug-effects on subliminal exposure to sexual stimuli.  
In summary, methylphenidate but not MDMA increased ratings of sexual excitation by 
visual stimuli with explicit sexual content but participants responded more to implicit stimuli 
after both drugs. Neither MDMA nor methylphenidate altered appraisal of romantic 
relationships of others. The findings are consistent with a role of DA in sexual drive. It 
remains to be studied whether sexual perception or even risk-associated sexual behavior is 
altered in subjects using methylphenidate chronically as a recreational drug, for cognitive 
enhancement, or as treatment for attention deficit hyperactivity disorder.  
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Figure 1. In the Sexual Arousal Task, pictures with sexual implicit or explicit content were 
rated significantly more “arousing/exciting” than neutral pictures (both p<0.001). 
Methylphenidate significantly increased ratings of “arousing/exciting” for pictures with an 
explicit sexual content compared with placebo (p<0.01) or MDMA (p<0.001). Data are 
expressed as mean ± SEM in 28 participants. **p < 0.01 and ***p < 0.001 for significant 
differences. Pla, placebo; MPH, methylphenidate; MDMA, 3,4-
methylenedioxymethamphetamine.  
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Figure 2. In the Couples Appraisal Task, neither methylphenidate nor MDMA altered 
appraisal of intimate relationships compared with placebo. Data are expressed as mean ± 
SEM in 30 participants. MDMA, 3,4-methylenedioxymethamphetamine.  
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Abstract 
Methylphenidate mainly enhances dopamine neurotransmission whereas 3,4-
methylenedioxymethamphetamine (MDMA, “ecstasy”) mainly enhances serotonin 
neurotransmission. However, both drugs also induce a weaker increase of cerebral 
noradrenaline exerting sympathomimetic properties. Dopaminergic psychostimulants are 
reported to increase sexual drive, while serotonergic drugs typically impair sexual arousal 
and functions. Additionally, serotonin has also been shown to modulate cognitive perception 
of romantic relationships. Whether methylphenidate or MDMA alter sexual arousal or 
cognitive appraisal of intimate relationships is not known. Thus, we evaluated effects of 
methylphenidate (40mg) and MDMA (75mg) on subjective sexual arousal by viewing erotic 
pictures and on perception of romantic relationships of unknown couples in a double-blind, 
randomized, placebo-controlled, crossover study in 30 healthy adults. Methylphenidate, but 
not MDMA, increased ratings of sexual arousal for explicit sexual stimuli. The participants 
also sought to increase the presentation time of implicit sexual stimuli by button press after 
methylphenidate treatment compared with placebo. Plasma levels of testosterone, estrogen, 
and progesterone were not associated with sexual arousal ratings. Neither MDMA nor 
methylphenidate altered appraisal of romantic relationships of others. The findings indicate 
that pharmacological stimulation of dopaminergic but not of serotonergic neurotransmission 
enhances sexual drive. Whether sexual perception is altered in subjects misusing 
methylphenidate e.g., for cognitive enhancement or as treatment for attention deficit 
hyperactivity disorder is of high interest and warrants further investigation. 
 
Keywords: MDMA, methylphenidate, sexual arousal, couples appraisal  
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Introduction  
Methylphenidate is a stimulant drug used for the treatment of attention deficit 
hyperactivity disorder, but it is also misused as a club drug and a cognitive enhancer (Maier 
et al., 2013). 3,4-Methylenedioxymethamphetamine (MDMA; “ecstasy”) is a popular 
recreational drug used primarily because of its empathogenic properties, i.e. the drug 
increases feelings of sociability and closeness to others (Hysek et al., 2013; Morgan et al., 
2013). Additionally, both drugs also have psychostimulant properties (Hysek et al., 2014). 
It is well recognized that psychoactive substances affect sexual behavior. Users of 
Many psychostimulants including cocaine and methamphetamine report increased subjective 
reports of sexual desire and arousal and enhanced to enhance sexual pleasure (Frohmader 
et al., 2010; Rawson et al., 2002; Semple et al., 2002). In contrast, ecstasy users described 
inconsistent effects of MDMA on sexual desire (McElrath, 2005; Passie et al., 2005; Theall et 
al., 2006). Specifically, most users report no desire for penetrative sex but only increased 
feelings of sensuality, whereas some (in particular gay and bisexual females) use MDMA in 
particular for sexual enhancement (McElrath, 2005). In another survey, similar proportions of 
users reported increased or decreased interest in initiating sexual activity while on MDMA 
(Buffum and Moser, 1986). , while Additionally, sexual performance seems to be consistently 
impaired by the drug (Buffum and Moser, 1986; Passie et al., 2005; Zemishlany et al., 2001). 
Thus, MDMA induces well-being and feelings of closeness to others (Hysek et al., 2013) 
accompanied by a sensual rather than a sexual enhancement (Passie et al., 2005).   
However, research on psychoactive drug use and sexual behavior is typically based on 
interviews of drug users and has mainly focused on sexual risk taking (McElrath, 2005; 
Rawson et al., 2002; Semple et al., 2002; Theall et al., 2006). Few studies have objectively 
evaluated sexual arousal in stimulant drug users (Aguilar de Arcos et al., 2008) or 
investigated the effects of acute administration of a psychostimulant on sexual perception 
(Volkow et al., 2007). In particular, intravenous administration of methylphenidate at a high 
dose of 0.5 mg/kg body weight has been shown to enhance self-reported sexual desire 
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(Volkow et al., 2007) while administration of a moderate oral dose of methylphenidate (20 
mg) had no effects (Volkow et al., 2007). Finally, to our knowledge there are no experimental 
data on the effects of MDMA on sexual perception and arousal.  
Methylphenidate increases dopamine (DA) and norepinephrine (NE) neurotransmission 
by DA and NA reuptake inhibition (Schmeichel and Berridge, 2013), while MDMA mainly 
releases serotonin (5-hydroxytryptamine, 5-HT) but also NE (Hysek et al., 2012b). While DA 
is thought to facilitate sexual drive, 5-HT is stated to inhibit sexual arousal and function 
(Fabre-Nys, 1998; Frohmader et al., 2010; Melis and Argiolas, 1995; Passie et al., 2005; 
Pfaus, 2009; Zemishlany et al., 2001). For example, dopaminergic antiparkinson therapy is 
associated with hypersexuality (Kelley et al., 2012; Uitti et al., 1989; Weintraub et al., 2010) 
whereas decreased libido and sexual dysfunction are common adverse effects of 
serotonergic antidepressants (Serretti and Chiesa, 2009). Accordingly, we hypothesized that 
methylphenidate (40 mg), predominantly enhancing DA, would increase sexual arousal in a 
Sexual Arousal Task (SAT), while MDMA (75 mg), mainly increasing 5-HT, would not. 
Because sex hormones may alter sexual arousal (Meston and Frohlich, 2000), we measured 
testosterone, estrogen, and progesterone plasma levels and explored possible associations 
with sexual arousal ratings.  
Besides from having effects on sexual desire and emotion, psychoactive drugs may 
also influence aspects of the cognitive appraisal of romantic partnerships. For example, 
MDMA has been shown to acutely alter related components of social cognition including 
recognition of facial emotions (Bedi et al., 2010; Hysek et al., 2012a; Hysek et al., 2013; 
Hysek et al., 2014; Kirkpatrick et al., 2014) and emotional empathy (Hysek et al., 2013; 
Kuypers et al., 2014; Schmid et al., 2014). Additionally, changes in 5-HT levels may influence 
cognitions sustaining intimate relationships. Specifically, healthy volunteers perceived 
photographed couples as being less intimate and romantic after lowering cerebral 5-HT 
levels by tryptophan depletion (Bilderbeck et al., 2011). In contrast, sub-chronic 
administration of the selective 5-HT reuptake inhibitor (SSRI) citalopram increased perceived 
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worth of mutual trust in relationships and reduced importance attributed to physical and 
intimate aspects of the participants’ own relationship (Bilderbeck et al., 2014). We therefore 
evaluated the effect of a 5-HT releaser (MDMA) and a DA and NA reuptake inhibitor 
(methylphenidate) on cognitive appraisal of intimate relationships. We hypothesized that 
MDMA, but not methylphenidate, would increase ratings of intimacy and romance in the 
Couples Appraisal Task (CAT) (Bilderbeck et al., 2011; Bilderbeck et al., 2014) parallel to its 
5-HT enhancing, empathogenic and prosocial effects (Hysek et al., 2013; Kirkpatrick et al., 
2014).  
 
Experimental Procedures 
Experimental protocol 
We used a double-blind, placebo-controlled, cross-over design in 30 subjects each treated 
with methylphenidate (40mg), MDMA (75 mg), and placebo, resulting in 90 assessments. 
The order of the three experimental sessions was balanced (Latin Square design), and the 
washout periods between sessions were at least seven days. The study was conducted in 
accordance with the Declaration of Helsinki and approved by the local Ethics Committee and 
the Swiss Agency for Therapeutic Products (Swissmedic). The study was registered at 
ClinicalTrials.gov (NCT01616407). All of the subjects provided written informed consent 
before participating in the study and were paid for their participation. 
 
Participants 
Thirty healthy subjects (15 men, 15 women) with a mean age of 24 ± 4.2 years (mean ± SD; 
range 18 to 32 years) were recruited from the University of Basel. All subjects were self-
reported heterosexuals. Inclusion criteria were age 18 to 45 years and body mass index 18 
to 27 kg/m2. The exclusion criteria were a history of psychiatric disorders (determined by the 
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Structured Clinical Interview for Axis I and II Disorders according to the Diagnostic and 
Statistical Manual of Mental Disorders, 4th edition) or chronic or acute physical illness 
(assessed by physical examination, electrocardiogram, standard hematology, and chemical 
blood analysis). Additional exclusion criteria were pregnancy, tobacco smoking (>10 
cigarettes/day), a lifetime history of using illicit drugs more than five times, with the exception 
of past cannabis use, and any illicit drug use including cannabis within the last two months or 
during the study period, determined by urine tests conducted during screening and before 
the test sessions using TRIAGE 8 (Biosite, San Diego, California). Twenty-two subjects were 
“ecstasy”/MDMA-naive. Eight subjects had used MDMA less than five times. One subject 
reported previous single use of methylphenidate as cognitive enhancer. Six female 
participants used hormonal contraception. The female subjects who did not use hormonal 
contraception were investigated during the follicular phase (day 2 to 14). 
Study drugs 
±MDMA hydrochloride (Lipomed AG, Arlesheim, Switzerland) was prepared as gelatin 
capsules with mannitol as filler. Identical placebo (only mannitol) capsules were prepared. 
MDMA was administered in a single absolute dose of 75 mg corresponding to 1.1 ± 0.13 
mg/kg body weight (range 0.8-1.3 mg/kg body weight). This dose of MDMA corresponds to 
that typically found in a single ecstasy pill (Brunt et al., 2012). Immediate-release 
methylphenidate tablets (4×10 mg, Ritalin, Novartis AG, Bern, Switzerland) were 
encapsulated within opaque gelatin capsules (with mannitol as filler), and identical placebo 
capsules (mannitol pill plus mannitol filler) were prepared. This is a typical and well-tolerated 
clinical and research dose of methylphenidate (Korostenskaja et al., 2008) producing similar 
cardiovascular stimulation to the dose of MDMA used (Schmid et al., 2014). 
 
Study procedures 
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The experimental sessions took place in a quiet hospital research ward with no more than 
two research subjects of the same sex present per session. Before the first session, subjects 
completed a brief training to get familiarized with the computer tasks. Drug administration 
was at 10:00 AM. The SAT and CAT were performed at 150 and 170 minutes after drug 
administration, respectively, when maximal plasma levels of the drugs were expected (Hysek 
et al., 2014). The actual times to peak concentration were (mean±SD) 153±50 and 130±48 
min after MDMA and methylphenidate administration, respectively, as reported together with 
the concentration-time curves (Schmid et al., 2014). A standardised small lunch was served 
at 13:30 PM. Subjects were sent home at 4:30 PM. During the day, subjective effects, vital 
signs and adverse drug effects were assessed as reported elsewhere (Schmid et al., 2014). 
Additional test of emotion recognition and empathy were performed 75-105 min after drug 
administration as reported elsewhere (Schmid et al., 2014).  
Measures 
Sexual Arousal Task 
The SAT included 16 colour photographs taken from the International Affective Picture 
System (IAPS) (Lang et al., 2008), as similarly used by others (Aguilar de Arcos et al., 2008). 
There were eight neutral and eight erotic or sexual pictures. Neutral pictures showed 
landscapes, objects, or persons without sexual signals. Erotic pictures included four implicit 
sexual scenes (i.e., no primary or secondary sexual organs are shown explicitly but persons 
where shown in stimulating poses showing some skin) and four explicit sexual scenes (i.e., 
clearly pornographic poses or scenes). In the neutral (persons), implicit and explicit 
condition, two pictures with single persons and two pictures with couples were shown, 
respectively. Thus, we had four pictures of neutral objects (two) and landscapes (two), four 
pictures of neutral persons (two singles and two couples), four pictures of implicit sexual 
scenes (two singles and two couples), and four pictures of explicit erotic scenes (two singles 
and two couples). Additionally, there was a male and a female version of the test: female 
subjects were only shown males in the single person condition, while male subjects received 
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only female single person stimuli. Because men and women were tested on different tasks, 
scores cannot be compared directly. The SAT included two subtasks, an “effort task” and an 
“arousal rating task”. In the effort task, pictures were shown for one sec. To prolong the 
presentation, participants were instructed to click rapidly on the keyboard for as long as they 
wanted to see the picture. One or more clicks per sec resulted in a prolongation of the 
presentation by another sec until no more clicks occurred within one sec. Outcome measures 
were the total number of clicks and the resulting duration the picture was presented. In the 
arousal rating task, participants were asked to rate each picture on 5 dimensions. The 
dimensions included “pleasant”, “arousing/exciting”, “attractive”, “likeable”, and “erotic”. The 
original Self-Assessment Manikin were used for the affective dimensions valence (“pleasant”) 
and arousal (“”arousing/exciting”) (Bradley and Lang, 1994), resulting in a 9-point rating 
scale. Ratings for “attractive”, “likeable” and “erotic” were performed on a 9-point rating scale 
marked “not at all” on the left and “very” on the right end. Ratings of all neutral, implicit sexual 
or explicit sexual pictures were averaged for each dimension. The SAT was implemented in 
Presentation Version 14.8 (Neurobehavioral Systems, Albany, CA, USA) and shown on a 
computer screen. 
Couples Appraisal Task  
To assess the appraisal of intimate relationships we used a German adaptation of the 
previously described CAT (Bilderbeck et al., 2011; Bilderbeck et al., 2014). Briefly, 18 
photographs of heterosexual couples in genuine relationships were presented on a computer 
screen. All facial expressions were broadly neutral. Nine couples showed physical contact 
such as affiliative or romantic gestures and nine couples were standing apart and were not 
touching each other. Touching and non-touching couples were randomly mixed. Participants 
rated each couple using visual analogue scales (0-10) with “not at all” and “very” as anchor 
points for the following descriptors, which were selected to display subjects’ perceived 
ratings of relationship stability (Bilderbeck et al., 2011; Bilderbeck et al., 2014): “intimate”, 
“romantic”, “supportive”, “trusting”, “conflict resolution”, “enduring”, and “good physical 
  Schmid et al.  
 
 9
relationship”. Ratings of “turbulence” and “bickering” were used as negative relationship 
characteristics. Additionally, “dominance” and “balance of love” were rated using scales 
labelled with “man” on the left and “woman” on the right, with “neutral” at the midpoint. 
Participants’ ratings for each of the descriptors were then averaged over touching and non-
touching couples. The CAT was also implemented in Presentation Version 14.8 
(Neurobehavioral Systems, Albany, CA, USA).  
Endocrine measures 
Plasma levels of testosterone (men and women), estradiol and progesterone (only women) 
were measured at baseline and 2 h after drug administration using commercial electro-
chemiluminescence immunoassays (Cobas ®, Roche Diagnostics, Basel, Switzerland).  
Data analysis 
Statistical analysis was performed using Statistica 12 (StatSoft, Tulsa, OK, USA). SAT data 
were analysed using analyses of variance (ANOVAs) with drug (methylphenidate, MDMA, 
placebo) and sexual content (neutral, implicit, explicit) as within-subject factors. Drug effects 
on ratings of couples in the CAT were similarly analysed using ANOVAs with drug and 
touching (touching vs. non-touching) as within-subject factor. ANOVAs were also used to 
compare hormone levels (differences from baseline, ∆Emax). Tukey post hoc were performed 
based on significant main effects or interactions. Sex-differences were assessed with sex 
added to the ANOVAs as between-subject factor for each descriptor.  Additional ANOVAs 
were performed with drug order to exclude carry-over effects. Spearman’s rank correlations 
were used to determine associations between measures. Differences associated with p-
values lower than 0.05 (two-tailed) were considered statistically significant. 
 
Results 
Sexual Arousal Task 
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Data from two women and two men were missing for the SAT effort task and for two women 
for the SAT arousal task due to technical problems. Effects of methylphenidate and MDMA 
on SAT scores are shown in Table 1 and Figure 1.  
In the effort subtask, there were significant drug × sexual content interactions for both the 
number of clicks and the duration of the presentation [F(4,100)=2.6; p<0.05 and 
F(4,100)=3.0, p<0.05; respectively]. There was a significant main effect of sexual content 
(neutral, implicit, explicit) on both the number of clicks [F(2,50)=18.3; p<0.001] and on the 
duration of the presentation [F(2,50)=22.2; p<0.001]. The total number of clicks was lower for 
explicit compared with implicit and neutral stimuli (both p<0.001). Both, methylphenidate and 
MDMA increased the number of clicks for implicit sexual stimuli compared with placebo 
(p<0.001 and p<0.01, respectively). Only methylphenidate also significantly increased the 
presentation time for the sexual implicit stimuli compared with placebo (p<0.05). 
In the arousal subtask, there were significant main effects of sexual content (neutral, implicit, 
explicit) for all ratings [all F(2,54)>50; p<0.001]. Implicit sexual content increased ratings on 
all dimensions compared with neutral contents (all p<0.001, Table 1) and ratings were also 
mostly higher compared with explicit sexual contents (most p<0.001). Explicit sexual content 
also increased ratings of arousal/excitement, attractiveness, and erotic. There was a 
significant drug × sexual content interaction on ratings of “arousing/exciting” [F(4,108) = 3.59; 
p<0.01]. Methylphenidate significantly increased ratings of arousal/excitement compared with 
placebo (p<0.01) or MDMA (p<0.001) for pictures with an explicit sexual content. 
Methylphenidate similarly tended to increase ratings of erotic compared with placebo and 
MDMA [F(4,108) = 2.17; p=0.08; both post hoc tests: p<0.05] (Table 1). MDMA did not alter 
any ratings compared with placebo. The findings remained largely the same when an 
analysis was altered to include, for the neutral condition, only the pictures displaying persons 
(i.e. excluding landscape and object pictures). Finally, introducing the additional factor 
“number of shown persons” (singles vs. couples) did also not change the results and the 
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factor itself was also not significant. Surprisingly, there were no significant differences 
between male or female participants in any of the ratings or drug effects.  
Couples Appraisal Task  
Drug effects in the CAT are shown in Figure 2. There were no drug effects on any of the 
descriptors in the CAT, indicating that neither methylphenidate nor MDMA altered appraisal 
of intimate relationship. In line with previous studies (Bilderbeck et al., 2011; Bilderbeck et 
al., 2014), ratings of all relationship stability descriptors (“intimate”, “romantic”, “supportive”, 
“trusting”, “conflict resolution”, “enduring”, and “good physical relationship”) were significantly 
increased for touching couples compared with couples who were standing apart [F(1.28)>10; 
p<0.01 for all descriptors]. Again, no sex differences or sex × drug interactions were 
observed.  
Endocrine measures 
Drug effects on plasma levels of testosterone, estradiol, and progesterone are shown in 
Table 2. There were no significant correlations between plasma sex hormone levels and 
sexual arousal ratings after any of the drugs (drug-induced changes or change scores 
[∆placebo-drug]). There was a significant main effect of drug on testosterone in women 
[F(2,28)=5.392; p<0.02] with slightly higher levels after methylphenidate compared with 
placebo (p<0.05). Additionally, there was a significant main effect of drug on estradiol 
[F(2,28)=4.672; p<0.02], with higher levels after methylphenidate compared with MDMA 
(p<0.05).  
 
Discussion 
The present experimental study showed that healthy adults rated pictures with an 
explicit sexual content as more exciting after acute administration of methylphenidate 
compared with placebo or MDMA. Concurrently, methylphenidate increased the number of 
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responses (button presses) performed by the participants in order to prolong the presentation 
of images with an implicit sexual content and the actual presentation duration of these 
pictures. In contrast, MDMA had no effect on subjective arousal ratings of erotic pictures with 
implicit or explicit sexual content. However, similar to methylphenidate, MDMA also 
increased the number of responses for implicit sexual stimuli but the invested effort was too 
small to significantly actually prolong the presentation time. Surprisingly, none of the drugs 
altered appraisal of romantic relationships in a task previously shown to be sensitive to 
alterations in the 5-HT system (Bilderbeck et al., 2011; Bilderbeck et al., 2014).  
Psychostimulants are believed to acutely increase sexual arousal and drive, but such 
effects have rarely been evaluated using actual tests and in controlled settings. Consistent 
with our findings, methylphenidate has previously been shown to increase self-reports of 
sexual desire (Volkow et al., 2007). However, the effect of methylphenidate on sexual desire 
was observed only after intravenous administration of methylphenidate but not after oral 
administration of a moderate dose of 20 mg (Volkow et al., 2007). Additionally, subjects rated 
their sexual desire in the absence of any sexual stimuli and while lying in a tomograph 
(Volkow et al., 2007). In contrast, in our study, subjects were viewing pictures with implicit 
and explicit sexual content and we evaluated drug effects on subjective sexual arousal 
elicited by these visual sexual stimuli. Moreover, we administered a higher dose of 
methylphenidate (40 mg), which might lead to similar plasma levels as intravenous 
administration of a lower dose (20 mg) in the study of Volkow and colleagues (Volkow et al., 
2007). Consistent with the present findings, other stimulants with similar dopaminergic action 
including cocaine and methamphetamine have been subjectively reported to increase sex 
drive as well (Rawson et al., 2002) and are commonly linked with risk-associated sexual 
behaviours (Frohmader et al., 2010; Rawson et al., 2002). Furthermore, abstinent cocaine 
users also rated explicit erotic pictures from the IAPS as more pleasant compared with users 
of alcohol or heroin (Aguilar de Arcos et al., 2008).  
  Schmid et al.  
 
 13
The mechanisms underlying increased sexual arousal following administration of 
psychoactive substances have only partly been elucidated. It has been proposed that DA is 
responsible for the increase in sexual arousal following administration of methylphenidate or 
methamphetamine by disrupting conditioned inhibition of sexual arousal and behaviour 
(Volkow et al., 2007) although these drugs also enhance NE in addition to DA.  
MDMA did not enhance subjective sexual arousal ratings in response to visual stimuli 
in the present study. However, MDMA, similar to methylphenidate, significantly increased the 
number of clicks to potentially prolong the presentation of the implicit but not of the explicit 
sexual stimuli compared with placebo. Viewing implicit erotic pictures was rated as more 
pleasant compared with viewing explicit pornographic pictures in all drug conditions. Thus, 
MDMA increased responding only for erotic stimuli that were more pleasant to view. 
Interviews of recreational MDMA users documented that most respondents reported feelings 
of emotional closeness while consuming MDMA but without the desire for penetrative sex 
(McElrath, 2005). However, other respondents reported that MDMA increased their sexual 
arousal and some (in particular gay and bisexual females) had used MDMA specifically for 
sexual enhancement (McElrath, 2005). Another interview study found that ecstasy use 
seemed to increase sexual desire but not the ability to achieve an erection or orgasm (Theall 
et al., 2006; Zemishlany et al., 2001). Thus, MDMA mainly seems to enhance pleasure in 
touching and physical closeness rather than actual sexual engagement and is also reported 
to impair sexual performance (Frohmader et al., 2010; Passie et al., 2005; Theall et al., 2006; 
Zemishlany et al., 2001). Neurochemically, MDMA enhances 5-HT and NE and weakly also 
DA transmission (Hysek et al., 2012b) but additionally, MDMA also releases oxytocin and 
prolactin (Hysek et al., 2012a; Hysek et al., 2013). Dopamine, NE and oxytocin enhance and 
5-HT and prolactin inhibit sexual excitation (Kruger et al., 2005; Pfaus, 2009). Sexual 
dysfunction associated with serotonergic drugs has been shown to involve 5-HT1B, 5-HT2 and 
5-HT3 receptors (Fabre-Nys, 1998; Meston and Frohlich, 2000). In addition to releasing 5-HT 
and NE (Hysek et al., 2012b), MDMA also directly binds to serotonergic 5-HT2A-, 5-HT2B-, 
and 5-HT2C-receptors (Simmler et al., 2013; Teitler et al., 1990). It is likely that the 
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serotonergic effects predominate in this neurochemical cocktail, resulting in the absence of 
sexually enhancing or even presence of impairing effects for MDMA at the doses typically 
used by humans.  
Sexual stimuli and behaviour activate the mesolimbic DA reward system similarly to 
other rewarding/pleasant stimuli or drugs of abuse (Georgiadis and Kringelbach, 2012; 
Holstege et al., 2003). Our study findings are consistent with the role for DA in sexual arousal 
because methylphenidate increased sexual arousal and MDMA did not. In the case of 
MDMA, the additional release of NE may have had some small sexually enhancing effects, 
which were masked by concomitant 5-HT release, which is known to dampen sexual function 
(Pfaus, 2009). Consistent with our finding of increased sexual arousal after methylphenidate, 
the DA precursor levodopa enhanced the activation of the nucleus accumbens when 
subliminal sexual stimuli were shown, whereas the DA D2-receptor antagonist haloperidol 
decreased activations (Oei et al., 2012). Accordingly, the DA and NE transporter inhibitor and 
antidepressant bupropion, which has less side effects on sexual arousal and libido than 
serotonergic antidepressants, increased activation of brain regions related to sexual 
functioning (Abler et al., 2011). Moreover, flibanserin, which enhances NE and DA while 
reducing 5-HT (Borsini et al., 2002), increased sexual desire in women with hypoactive 
sexual desire (Katz et al., 2013). Finally, dextroamphetamine and methylphenidate have 
been reported to reverse the sexually impairing effects of 5-HT transporter blockers and to 
even enhance sexual arousal and function in female and male patients with depression 
(Bartlik et al., 1995).  
Although MDMA did not enhance sexual arousal in the present study, it appears to 
induce effects that may affect sexual interaction. In particular, MDMA increased feelings of 
closeness to others and sociability and alters sensual perception including touch (Hysek et 
al., 2013; Liechti et al., 2001; Schmid et al., 2014). Despite these emotional changes, MDMA 
did not alter the appraisal of romantic partnerships of others in the present study contrary to 
our expectation. It has previously been shown that presumably enhancing 5-HT tone with 
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citalopram across eight days increased ratings of trusting in the CAT and reduced the 
importance of physical and intimate aspects of the participant’s own relationships (Bilderbeck 
et al., 2014). Contrarily, lowering cerebral 5-HT by tryptophan depletion has changed ratings 
of relationship characteristics of photographed couples, including decreased intimacy and 
romance (Bilderbeck et al., 2014). Alterations in 5-HT levels did not only influence 
relationship characteristic ratings but also ratings of dominance with women providing higher 
ratings of male dominance after 5-HT reduction (Bilderbeck et al., 2011), and decreased 
ratings of turbulence and bickering in men after citalopram (Bilderbeck et al., 2014). 
However, MDMA was administered acutely while citalopram was administered chronically 
probably resulting in adaptive changes to the 5-HT system (Stahl, 1998). Additionally, MDMA 
is also less selective for the 5-HT system than citalopram (see above). Moreover, although 
MDMA stimulates 5-HT release much more than citalopram, it did not alter ratings of general 
relationship stability or indices of dominance and discord in the CAT. Thus, we might have 
“overstimulated” our participants as – similar to DA and NE neurotransmission – an inverted 
U-shaped function has also been postulated for the 5-HT system (Roiser et al., 2006). 
Interestingly, MDMA produced subjective feelings of trust and openness towards others 
(Schmid et al., 2014), thus producing effects that were very similar to those perceived 
important in others after citalopram administration (Bilderbeck et al., 2014).  
While pathologically low levels of testosterone result in decreased sexual interest and 
activity, variability in the normal/upper range is generally not considered to influence sexual 
interest or behavior in men (Meston and Frohlich, 2000). Similarly, estrogen and 
progesterone play only a minimal role in female sexual desire (Meston and Frohlich, 2000). 
We found that plasma levels of testosterone, estrogen, or progesterone were not associated 
with sexual arousal ratings in the present study. Consistently, different estrogen and 
progesterone levels exerted only minor effects on neural responses to explicit visual erotic 
stimulation in women (Abler et al., 2013).   
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The present study has several limitations. First, we used only single doses of MDMA 
and methylphenidate. However, the used doses of both drugs that produced similar 
cardiovascular stimulation (Schmid et al., 2014), indicating equipotent stimulant effects. 
Nevertheless, dose-response relationships are lacking as in most of such human 
neuropsychopharmacological experiments. As an important strength, we included two active 
drugs into the design allowing for comparisons of each active drug with both the placebo and 
another active drug condition. Second, only acute drug effects were assessed and the impact 
of chronic use of methylphenidate or MDMA on the present measures remains unknown. 
Third, sexual stimuli were presented without time limit. It has previously been shown that 
exposure to supraliminal sexual images showed activation in both arousal- but also control-
related brain areas (Gillath and Canterberry, 2012). Men presumably show higher sexual 
drive (Baumeister et al., 2001), but may also exhibit stronger urge to control it when being 
consciously aroused, therefore resulting in similar arousal ratings than women. Future 
studies will have to examine drug-effects on subliminal exposure to sexual stimuli.  
In summary, methylphenidate but not MDMA increased ratings of sexual excitation by 
visual stimuli with explicit sexual content but participants responded more to implicit stimuli 
after both drugs. Neither MDMA nor methylphenidate altered appraisal of romantic 
relationships of others. The findings are consistent with a role of DA in sexual drive. It 
remains to be studied whether sexual perception or even risk-associated sexual behavior is 
altered in subjects using methylphenidate chronically as a recreational drug, for cognitive 
enhancement, or as treatment for attention deficit hyperactivity disorder.  
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Figure 1. In the Sexual Arousal Task, pictures with sexual implicit or explicit content were 
rated significantly more “arousing/exciting” than neutral pictures (both p<0.001). 
Methylphenidate significantly increased ratings of “arousing/exciting” for pictures with an 
explicit sexual content compared with placebo (p<0.01) or MDMA (p<0.001). Data are 
expressed as mean ± SEM in 28 participants. **p < 0.01 and ***p < 0.001 for significant 
differences. Pla, placebo; MPH, methylphenidate; MDMA, 3,4-
methylenedioxymethamphetamine.  
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Figure 2. In the Couples Appraisal Task, neither methylphenidate nor MDMA altered 
appraisal of intimate relationships compared with placebo. Data are expressed as mean ± 
SEM in 30 participants. MDMA, 3,4-methylenedioxymethamphetamine.  
 
 
 
 
 
 
Table 1. Drug effects in the Sexual Arousal Task. 
neutral implicit sexual explicit sexual neutral implicit sexual explicit sexual neutral implicit sexual 
Effort Task 
number of clicks 4.96±0.72 3.50±0.70 2.35±0.60
+++
6.27±0.80 5.81±0.74*** 2.85±0.74
+++
5.31±0.90 5.58±0.79**
duration of presentation (sec) 3.12±0.38 2.38±0.41 1.35±0.35
+++
3.23±0.39 3.42±0.40* 1.46±0.38
+++
2.81±0.43 3.23±0.39
Arousal Rating Task
pleasant 5.70±0.18 6.38±0.23
+++
4.59±0.23
+++ 5.81±0.13 6.78±0.15
+++
5.05±0.25
++ 5.76±0.15 6.72±0.20
++
arousing/exciting 3.66±0.18 5.81±0.24
+++
5.33±0.30
+++ 3.79±0.16 6.13±0.15
+++
6.06±0.22**
###+++ 3.83±0.19 5.95±0.21
+++
attractive 4.10±0.21 6.56±0.27
+++
4.75±0.27
++ 4.35±0.17 6.84±0.16
+++
5.22±0.25
+++ 4.25±0.18 6.74±0.20
+++
likeable 4.64±0.23 6.15±0.23
+++
4.07±0.23
+ 5.00±0.19 6.34±0.17
+++
4.35±0.20
++ 4.75±0.23 6.38±0.21
+++
erotic 2.94±0.17 5.84±0.31
+++
5.25±0.36
+++ 3.09±0.15 6.31±0.23
+++
5.84±0.30
+++ 3.15±0.19 5.96±0.23
+++
Placebo Methylphenidate MDMA
Values are mean±SEM in 26 subjects (effort task) and 28 subjects (arousal task). *p < 0.05, ** p < 0.01  and ***p < 0.001 compared with placebo;  ### p < 0.001 compared with MDMA (same sexual content). + p 
< 0.05, 
++
 p < 0.01, 
+++
 p < 0.001 compared with the respective neutral stimuli (same drug condition).
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Table 2. Endocrine measures.  
Placebo Methylphenidate MDMA
Testosterone (nmol/l)
men baseline 19.8±1.54 20.3±1.37 20.9±1.59
at 120 min 18.9±1.50 19.5±1.41 19.8±1.65
ΔEmax  -0.89±0.86  -0.81±0.85  -1.62±0.74
women baseline 1.01±0.10 1.01±0.11 1.10±0.11
at 120 min 0.79±0.10 0.99±0.12 0.99±0.12
ΔEmax  -0.22±0.04  -0.03±0.05*  -0.10±0.05
Progesterone (nmol/l)
women baseline 2.90±0.82 2.28±0.31 6.93±4.32
at 120 min 2.37±0.75 1.91±0.27 5.91±3.28
ΔEmax  -0.53±0.10  -0.37±0.11  -1.02±1.10
Estradiol (pmol/l)
women baseline 93±16 162±63 163±39
at 120 min 90±14 176.67±61 154±37
ΔEmax  -2.85±5.19 14.5±6.24#  -8.6±7.22
Values are mean ± SEM in 15 subjects. * p < 0.05 compared with placebo.  # p < 0.05 compared 
with MDMA.
Table 2
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